LEHI, Utah, Nov. 27, 2023 /PRNewswire/ -- Halia Therapeutics, a clinical-stage biopharmaceutical company advancing innovative medicines to treat a broad range of diseases driven by chronic inflammation and neurodegeneration, today announced that it will be presenting at the upcoming 65th American Society of Hematology (ASH) Annual Meeting and Exposition, which will take place December 9 – 12, 2023, in San Diego, California, and virtually.
ASH is one of the largest gatherings of the international hematology community, bringing together experts in the field to discuss the latest research in pathogenesis and clinical treatment of hematologic diseases. Halia will present a company showcase, which will provide an overview of the company's mission, values, and therapeutics currently in development for chronic inflammatory and neurological diseases targeting the NLRP3 inflammasome. The company will have an exhibition booth at the event and will be presenting 3 posters with new positive preclinical data that supports the development of its lead asset, HT-6184, the first drug candidate to target the protein NEK7 through an allosteric mechanism to inhibit NLRP3 inflammasome activity, in multiple indications.
"We look forward to engaging with other experts, fostering current and new collaborations, and establishing valuable connections with top researchers at ASH," said Dr. Dave J. Bearss, CEO and President of Halia Therapeutics. "We are delighted to showcase our company and highlight the importance of our novel approach in targeting the NLRP3 inflammasome. We are especially thrilled to present, for the first time, preliminary data highlighting the efficacy of our lead asset, HT-6184, in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) indications, as we believe that targeting this pathway holds significant promise for many additional hematological diseases".
Information on the presentations is listed below.
Company Showcase Presentation Details
Title: Halia Therapeutics – Targeting the Chronic Inflammatory Bone Marrow Microenvironment
Date: Sunday, December 10, 2023
Presenter: David Bearss, Ph.D., CEO of Halia Therapeutics and Alan List, MD, Halia Therapeutics
Time: 4:00 PM – 4:15 PM PT
Location: Room 5B (San Diego Convention Center)
Poster Presentations:
Title: The Dual Inflammasome/Myddosome Inhibitor HT-6184 Restores Erythropoiesis in MDS/AML
Date: Saturday, December 9, 2023
Session Name: 604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster I
Presenter: Amit Verma, MD
Time: 5:30 PM - 7:30 PM PT
Location: San Diego Convention Center, Halls G-H
Publication Number: 1417
Title: Modulation of NLRP3 Inflammasome in Monocytes By HT-6184 in a Single-Cell Proteomic Study
Date: Saturday, December 9, 2023
Session Name: 201. Granulocytes, Monocytes, and Macrophages: Poster I
Presenter: Devan Bursey, MS
Time: 5:30 PM - 7:30 PM PT
Location: San Diego Convention Center, Halls G-H
Publication Number: 1170
Title: HT-6184 Inhibits the Formation of the NLRP3 Inflammasome in Human Monocytic THP-1 Cells
Date: Monday, December 11, 2023
Session Name: 201. Granulocytes, Monocytes, and Macrophages: Poster III
Presenter: Ben Bearss, MS
Time: 6:00 PM - 8:00 PM PT
Location: San Diego Convention Center, Halls G-H
Publication Number: 3916
About NLRP3
Activation of NLRP3 triggers the release of the pro-inflammatory cytokines IL-1β and IL-18 and induces a lytic cell death process called pyroptosis. These processes lead to systemic chronic inflammation. Halia's therapeutic inhibition of NLRP3 prevents the formation of the NLRP3 inflammasome and promotes its disassembly once formed, thereby inhibiting the production and release of IL-1β and IL-18. Persistent activation of the NLRP3 inflammasome is thought to drive the onset and progression of many conditions, including fibrotic, dermatological, and auto-inflammatory diseases. Significant neurological disorders such as Alzheimer's disease, Parkinson's disease, and multiple sclerosis are also driven by prolonged NLRP3 activation.
About HT-6184
HT-6184 is the first drug candidate to target the protein NEK7 through an allosteric mechanism. NEK7 is an essential component of the NLRP3 inflammasome and is critical for its assembly and the maintenance of NLRP3 activity. In preclinical models, Halia has shown that inhibiting the ability of NEK7 to bind to NLRP3 leads to a disruption in the formation of the NLRP3 inflammasome complex, thereby inhibiting the signaling from the inflammasome and reducing the inflammatory response. Preclinical models also showed that in addition to disrupting the formation of the NLRP3 inflammasome, HT-6184 promotes the disassembly of the inflammasome once activated.
About Halia Therapeutics, Inc.
Halia Therapeutics is discovering and developing a pipeline of novel therapeutics to improve patients' lives with chronic inflammatory disorders and neurodegenerative diseases, with its initial programs targeting NEK7 and LRRK2. Halia's lead candidate, HT-6184, a novel NEK7/NLRP3 inhibitor, has completed a Phase 1 study (NCT05447546) evaluating the safety and tolerability of HT-6184 when administered as single or multiple oral doses at escalating dose levels in healthy volunteer subjects. The company is headquartered in Lehi, Utah. For more info, visit www.haliatx.com or follow us on LinkedIn and Twitter (X).
Company Contact:
James Dye
Info@haliatx.com
+1.385.355.4315
Media Contact:
Ignacio Guerrero-Ros, Ph.D.
Russo Partners, LLC
Ignacio.Guerrero-Ros@russopartnersllc.com
+1 (646) 942-5604
SOURCE Halia Therapeutics